2020 Q3 BQ Journal Vol 40 - 2

ZILRETTA
has a permanent,
product-specific J-code

J3304
CHRONIC OA KNEE PAIN
MEET YOUR MATCH
The first and only approved treatment for OA knee pain utilizing
extended-release microsphere technology
To order ZILRETTA, contact your Henry Schein Sales
Consultant or visit www.henryschein.com/medical
To learn more about ZILRETTA, call 781-562-4389
or email GetZ@flexiontherapeutics.com

ZILRETTA is not interchangeable with other formulations of injectable triamcinolone acetonide.

INDICATION AND IMPORTANT SAFETY INFORMATION
* Alterations in Endocrine Function: Corticosteroids can produce
reversible hypothalamic-pituitary-adrenal axis suppression, with
potential for adrenal insufficiency after withdrawal of treatment,
which may persist for months. In situations of stress during that period,
institute corticosteroid replacement therapy.
* Cardiovascular and Renal Effects: Corticosteroids can cause
blood pressure elevation, salt and water retention, and increased
potassium excretion. Monitor patients with congestive heart failure,
hypertension, and renal insufficiency for edema, weight gain,
and electrolyte imbalance. Dietary salt restriction and potassium
supplementation may be needed.
* Increased Intraocular Pressure: Corticosteroid use may be associated
with increased intraocular pressure. Monitor patients with elevated
intraocular pressure for potential treatment adjustment.
* Gastrointestinal Perforation: Corticosteroid administration may
increase risk of gastrointestinal perforation in patients with certain GI
disorders and fresh intestinal anastomoses. Avoid corticosteroids in
these patients.
* Alterations in Bone Density: Corticosteroids decrease bone formation
and increase bone resorption. Special consideration should be given to
patients with or at increased risk of osteoporosis prior to treatment.
* Behavior and Mood Disturbances: Corticosteroids may cause adverse
psychiatric reactions. Prior to treatment, special consideration should
be given to patients with previous or current emotional instability or
psychiatric illness. Advise patients to immediately report any behavior or
mood disturbances.
Adverse Reactions
The most commonly reported adverse reactions (incidence ≥1%)
in clinical studies included sinusitis, cough, and contusions.
Please see brief summary of full Prescribing Information on the adjacent page.

Indication
ZILRETTA ® (triamcinolone acetonide extended-release
injectable suspension) is indicated as an intra-articular injection for the
management of osteoarthritis pain of the knee.
Limitation of Use: The efficacy and safety of repeat administration of
ZILRETTA have not been demonstrated.
Contraindication
ZILRETTA is contraindicated in patients who are hypersensitive to
triamcinolone acetonide, corticosteroids, or any components of the
product.
Warnings and Precautions
* Intra-articular Use Only: ZILRETTA has not been evaluated and should
not be administered by epidural, intrathecal, intravenous, intraocular,
intramuscular, intradermal, or subcutaneous routes. Serious events
have been reported with epidural and intrathecal administration of
corticosteroids and none are approved for this use. ZILRETTA should
not be considered safe for epidural or intrathecal administration.
* Hypersensitivity Reactions: Rare instances of anaphylaxis, including
serious cases, have occurred in patients with hypersensitivity to
corticosteroids.
* Joint Infection and Damage: A marked increase in pain accompanied
by local swelling, restriction of joint motion, fever, and malaise are
suggestive of septic arthritis. Examine joint fluid to exclude a septic
process. If diagnosis is confirmed, institute appropriate antimicrobial
therapy. Avoid injecting corticosteroids into a previously infected or
unstable joint. Intra-articular administration may result in damage to
joint tissues.
* Increased Risk of Infections: Infection with any pathogen in any
location of the body may be associated with corticosteroid use.
Corticosteroids may increase the susceptibility to new infection and
decrease resistance and the ability to localize infection.

Learn more at ZilrettaPro.com
January 2020. Z-01076

Diagnostics I Pharmaceuticals I DxRx Solutions I Continuing Education I News
A Henry Schein Publication

20MS5677_BQ_journal_40.indd 2

7/13/20 12:18 PM

http://www.henryschein.com/medical http://www.ZilrettaPro.com

2020 Q3 BQ Journal Vol 40

Table of Contents for the Digital Edition of 2020 Q3 BQ Journal Vol 40